论文部分内容阅读
[目的]探讨血清CA15-3对预测乳腺癌、肺癌转移的临床应用价值。[方法]应用化学发光免疫分析技术检测了3995例乳腺癌、1269例肺癌患者血清CA15-3水平。[结果]3995例乳腺癌患者中,未转移患者CA15-3中位数为10.1U/ml;转移患者CA15-3中位数为32.4U/ml。1269例肺癌患者中,未转移患者CA15-3中位数为12.9U/ml;转移患者CA15-3中位数为19.7U/ml。两组肿瘤患者中,转移患者血清CA15-3显著高于未转移的肿瘤患者。[结论]血清CA15-3检测对乳腺癌、肺癌转移的预测有重要参考价值。
[Objective] To investigate the clinical value of serum CA15-3 in predicting the metastasis of breast cancer and lung cancer. [Method] The levels of serum CA15-3 in 3995 cases of breast cancer and 1269 cases of lung cancer were detected by chemiluminescence immunoassay. [Results] The median of CA15-3 in non-metastatic patients was 10.1 U / ml among 3995 cases of breast cancer; the median of CA15-3 in metastatic patients was 32.4 U / ml. Among 1269 lung cancer patients, the median CA15-3 in non-metastatic patients was 12.9 U / ml; the median CA15-3 in metastatic patients was 19.7 U / ml. Among the two groups of cancer patients, the serum CA15-3 levels in patients with metastasis were significantly higher than those in non-metastatic tumor patients. [Conclusion] Serum CA15-3 detection has important reference value for the prediction of breast cancer and lung cancer metastasis.